Immunexpress Awarded Grant to Bring Sepsis MDx Assay to Market
News Feb 19, 2014
“This is an important step forward in the development of SeptiCyte® PLUS and our efforts to bring novel sepsis assays to health care centers and patients around the world,” said Dr Roslyn Brandon, President and Chief Executive Officer, Immunexpress. “Based on the results to date, SeptiCyte® PLUS has the potential to make an important impact on the health care community and improve patient outcomes by allowing for earlier diagnosis and targeted antimicrobial treatment within a clinically relevant time frame of under three hours.“
The grant funding, along with existing cash resources, will be used to develop the SeptiCyte® PLUS prototype through to a Laboratory Developed Test (LDT), and make it available to hospital labs at two large health systems in the U.S. along with one major academic hospital in Germany. The prospective data collected through these centers is expected to inform the regulatory pathway and future medical device application for SeptiCyte® PLUS in the U.S.
New technologies that allow for the earlier detection and personalized management of people with, or at risk of, sepsis could significantly reduce the financial burden on health care systems worldwide through reduced patient mortality and morbidity; reduced stays in hospital and intensive care units (ICUs); more targeted use of antibiotics and anti-inflammatories; and reduced antimicrobial resistance.
CRISPR Study Reveals Errors in Earlier Cancer ResearchNews
MELK, a protein previously thought to be implicated in cancer, has been shown to be unrelated to the disease.READ MORE